Latest Leishmaniasis Stories
AHMEDABAD, India, April 23, 2015 /PRNewswire/ -- Etna Biotech, the Vaccine R & D subsidiary of Zydus, announced a collaborative program with the National Institute
Unhealing Ulcers Afflict Millions, Including U.S.
A new way to test for the parasite which causes the fatal disease leishmaniasis could help control its spread to humans and stop dogs being needlessly killed in parts of South America.
The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year.
Visceral Leishmaniasis (VL) is a severe chronic systemic disease caused by the protozoa (Leishmania infantum) in South America, the Mediterranean, southwest and central Asia.
Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought.
An international collaboration of researchers from the U.S. Army Medical Research and Materiel Command (USAMRMC), Tunisia and France has demonstrated a high cure rate and remarkably few side effects in treating patients with cutaneous leishmaniasis (CL) with an investigational antibiotic cream.
A research coordinated by the UAB has succeeded in testing a vaccine against leishmaniasis.
- An armed gangster.